Daewoong Pharmaceutical plans $74.6M botulinum toxin plant in Hwaseong

Daewoong Pharmaceutical plans to invest 100 billion won ($74.6 million) to build a third botulinum toxin production facility in Hwaseong, Gyeonggi Province, South Korea. Construction is expected to start in H1 2023 and be completed by 2024, adding capacity for up to 18 million vials per year.

“With the construction of the third plant, we will expand the Nabota business in earnest, including entering the therapeutic indication market and the Chinese market, and developing next-generation formulations.”fiercepharma.com

• 1 source
• fiercepharma.comDaewoong plots new $74.6M factory to pump out Botox rivalJoseph KeenanMay 3, 2023

Summarized from public sources; check the original articles before acting on it.